HDAC Class I Inhibitor Domatinostat Sensitizes Pancreatic Cancer to Chemotherapy by Targeting Cancer Stem Cell Compartment via FOXM1 Modulation

Scientists investigated the potential of domatinostat, a new class I histone deacetylase inhibitor, currently in clinical development, to sensitize PDAC to first line standard gemcitabine/taxol doublet chemotherapy treatment.